Sai Parenterals subsidiary wins AUD 202M Australian OTC supply deal

Order Above 5pct RevenueExport Order Hard CurrencyBusiness Updates View source PDF Explain this filing

SAIPARENT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹617.95

prior close

₹676.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+0.2% vs market

Pharmaceuticals peers, median of 164sector+0.0%+1.0% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 1.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.2

10m

-4.5

15m

-6.0

30m

-5.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.9+0.2+0.0+1.0

Next day

+0.4+0.5-0.1+0.5-0.0

-1.3+0.7-2.0+0.0-1.3

-3.2+0.0-3.3-0.3-2.9

-4.4-2.0-2.4-1.2-3.2

-3.9-0.1-3.7-0.7-3.2

-5.0+1.4-6.4+0.4-5.4

15d

-13.1-1.4-11.7-1.4-11.7

-10.7+1.3-12.0-0.3-10.4

-16.4+3.8-20.1+1.1-17.4

-19.9+2.9-22.8+0.5-20.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Parenterals' subsidiary Noumed Pharmaceuticals has signed an exclusive 7.5-year OTC medicine supply agreement with Australia's leading pharmacy network. The contract value is AUD 202 million, roughly equal to INR 1,300 crores. Deal starts July 1, 2026, with an option to extend by 3 more years on mutual consent. It is an international contract and not a related-party transaction.

Likely market impact

Major export win worth around INR 1,300 crores over 7.5 years strengthens long-term revenue visibility for retail shareholders.